Kadar Antibodi Anti-dsDNA dan Urine Monocyte Chemoattractant Protein-1 pada Nefritis Lupus

Urine Monocyte Chemoattractant Protein-1(UMCP-1) as a Biomarker of Renal Involvement in Systemic Lupus Erythematosus

Objective(s)Lupus nephritis (LN) is frequently associated with a poor long-term prognosis. Renal biopsy is the diagnostic method of choice in this condition. Urine biomarkers have been mentioned in the diagnosis of LN. The study,s purpose was to evaluate the performance of urinary monocyte chemoattractant protein 1(UMCP-1) as a biomarker of renal involvement in systemic lupus erythematosus.Mate...

urine monocyte chemoattractant protein-1(umcp-1) as a biomarker of renal involvement in systemic lupus erythematosus

objective(s)lupus nephritis (ln) is frequently associated with a poor long-term prognosis. renal biopsy is the diagnostic method of choice in this condition. urine biomarkers have been mentioned in the diagnosis of ln. the study,s purpose was to evaluate the performance of urinary monocyte chemoattractant protein 1(umcp-1) as a biomarker of renal involvement in systemic lupus erythematosus.mate...

Monocyte Chemoattractant Protein-1 Synthesis

Urine Monocyte Chemoattractant Protein-1(UMCP-1) as a Biomarker of Renal Involvement in Systemic Lupus Erythematosus

OBJECTIVES Lupus nephritis (LN) is frequently associated with a poor long-term prognosis. Renal biopsy is the diagnostic method of choice in this condition. Urine biomarkers have been mentioned in the diagnosis of LN. The study(,)s purpose was to evaluate the performance of urinary monocyte chemoattractant protein 1(UMCP-1) as a biomarker of renal involvement in systemic lupus erythematosus. ...

Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal Study

Objective. This longitudinal study aimed to determine the urine monocyte chemoattractant protein-1 (uMCP-1) levels in patients with biopsy-proven lupus nephritis (LN) at various stages of renal disease activity and to compare them to current standard markers. Methods. Patients with LN-active or inactive-had their uMCP-1 levels and standard disease activity markers measured at baseline and 2 and...